Impact of eptinezumab on work productivity beyond reductions in monthly migraine days: Post hoc analysis of the DELIVER trial

被引：2
|
作者：
Barbanti, Piero [1 ]
Awad, Susanne F. [2 ]
Regnier, Stephane A. [2 ]
Lee, Xin Ying [2 ]
Goadsby, Peter J. [3 ,4 ]
机构：
[1] IRCCS San Raffaele, Headache & Pain Unit, Milan, Italy
[2] H Lundbeck & Co AS, Valby, Denmark
[3] Kings Coll London, NIHR Kings Clin Res Facil, London, England
[4] Kings Coll London, Headache Grp, London, England
来源：
NEUROLOGY | 2023年 / 100卷 / 17期
关键词：
D O I：
10.1212/WNL.0000000000202965
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P13-12.012
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Impact of eptinezumab on work productivity beyond reductions in monthly migraine days: post hoc analysis of the DELIVER trial
    Barbanti, Piero
    Awad, Susanne F.
    Rae-Espinoza, Heather
    Regnier, Stephane A.
    Lee, Xin Ying
    Goadsby, Peter J.
    JOURNAL OF PATIENT-REPORTED OUTCOMES, 2024, 8 (01)
  • [2] Long-term reductions in acute headache medication use after eptinezumab treatment in patients with migraine and prior preventive treatment failures: Post hoc analysis of the DELIVER randomized trial
    Gryglas-Dworak, Anna
    Schim, Jack
    Ettrup, Anders
    Boserup, Line Pickering
    Josiassen, Mette Krog
    Ranc, Kristina
    Sperling, Bjrn
    Ashina, Messoud
    HEADACHE, 2025, 65 (01): : 101 - 112
  • [3] Responder rates with eptinezumab over 24 weeks in patients with prior preventive migraine treatment failures: post hoc analysis of the DELIVER randomized clinical trial
    Ashina, Messoud
    Lipton, Richard B.
    Ailani, Jessica
    Versijpt, Jan
    Sacco, Simona
    Mitsikostas, Dimos D.
    Christoffersen, Cecilie Laurberg
    Sperling, Bjorn
    Ettrup, Anders
    EUROPEAN JOURNAL OF NEUROLOGY, 2024, 31 (02)
  • [4] Eptinezumab demonstrated efficacy regardless of prior preventive migraine treatment failure: Post hoc DELIVER analyses
    Pozo-Rosich, Patricia
    Ashina, Messoud
    Tepper, Stewart J.
    Jensen, Sidsel
    Boserup, Line Pickering
    Josiassen, Mette Krog
    Sperling, Bjorn
    CEPHALALGIA, 2023, 43 (1supp) : 227 - 227
  • [5] Monthly Migraine Days, Acute Medication Use Days, and Migraine-Specific Quality of Life in Responders to Atogepant: A Post Hoc Analysis
    Dodick, D.
    Lipton, R.
    Nahas, S.
    Pozo-Rosich, P.
    McAllister, P.
    Mechtler, L.
    Ma, J.
    Dabruzzo, B.
    Dufek, M.
    Severt, L.
    Finnegan, M.
    Trugman, J.
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
  • [6] Monthly migraine days, acute medication use days, and migraine-specific quality of life in responders to atogepant: A post hoc analysis
    Dodick, D. W.
    Lipton, R. B.
    Nahas, S. J.
    Pozo-Rosich, P.
    McAllister, P.
    Mechtler, L. L.
    Ma, J.
    Dabruzzo, B. L.
    Dufek, M.
    Severt, L.
    Finnegan, M.
    Trugman, J. M.
    HEADACHE, 2022, 62 : 152 - 153
  • [7] Eptinezumab Demonstrated Efficacy Regardless of Prior Preventive Migraine Treatment Failure Type: Post Hoc Analyses of the DELIVER Study
    Pozo-Rosich, Patricia
    Ashina, Messoud
    Tepper, Stewart J.
    Jensen, Sidsel
    Boserup, Line Pickering
    Josiassen, Mette Krog
    Sperling, Bjorn
    NEUROLOGY AND THERAPY, 2024, 13 (02) : 339 - 353
  • [8] Eptinezumab Demonstrated Efficacy Regardless of Prior Preventive Migraine Treatment Failure Type: Post Hoc Analyses of the DELIVER Study
    Patricia Pozo-Rosich
    Messoud Ashina
    Stewart J. Tepper
    Sidsel Jensen
    Line Pickering Boserup
    Mette Krog Josiassen
    Bjørn Sperling
    Neurology and Therapy, 2024, 13 : 339 - 353
  • [9] Change in Migraine Diagnosis After Preventive Treatment With Eptinezumab: Post Hoc Analysis of the PROMISE Studies
    Pozo-Rosich, P.
    Dodick, D.
    Ettrup, A.
    Hirman, J.
    Cady, R.
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
  • [10] Change in migraine diagnosis after preventive treatment with eptinezumab: Post hoc analysis of the PROMISE studies
    Pozo-Rosich, P.
    Dodick, D. W.
    Ettrup, A.
    Hirman, J.
    Cady, R.
    HEADACHE, 2022, 62 : 134 - 134
12345